Dorsomorphin (Compound C): Applied Workflows for AMPK and BMP Inhibition

Principles and Setup: Harnessing Dorsomorphin’s Dual Pathway Inhibition

Dorsomorphin (Compound C), supplied by APExBIO, is a potent, reversible, ATP-competitive AMPK inhibitor (Ki = 109 nM) that also blocks BMP/Smad signaling. Its high selectivity for AMPK over related kinases, such as PKA, PKC, and JAK3, makes it an invaluable tool for dissecting metabolic and developmental pathways in diverse cell and animal models. The compound's ability to inhibit AMPK activity in hepatocytes and HeLa cells, suppress ACC phosphorylation by up to 80%, and regulate autophagic proteolysis underpins its broad experimental utility. Additionally, Dorsomorphin’s function as a BMP signaling inhibitor—particularly in blocking BMP4-induced SMAD phosphorylation (IC50 = 0.47 μM)—positions it as a dual-action molecule with applications spanning iron metabolism modulation, neural stem cell differentiation, and cancer research.

This duality is reflected in recent translational studies, such as Lei et al. (2025), which highlights AMPK’s role in regulating M1 macrophage polarization and airway inflammation through the JAK2/STAT3 pathway in obesity-related asthma. By leveraging Dorsomorphin, researchers can interrogate these interconnected metabolic and inflammatory circuits with high specificity.

• Solubility and Storage: Dorsomorphin is insoluble in water and ethanol but dissolves in DMSO at ≥8.49 mg/mL with gentle warming/ultrasonic treatment. Store as a solid at -20°C; prepare fresh DMSO solutions for immediate use.
• Recommended Concentrations: 4–40 μM for cell culture; 10 mg/kg via intraperitoneal injection in animal models.

Step-by-Step Experimental Workflows and Protocol Enhancements

1. Inhibition of AMPK Activity in Hepatocytes and Cell Lines

1. Thaw and dissolve Dorsomorphin (Compound C) in DMSO (≥8.49 mg/mL), using gentle warming and ultrasonic treatment for complete dissolution.
2. Add the DMSO stock to culture medium (final DMSO concentration ≤0.1%) to achieve desired working concentrations (typically 10–20 μM for AMPK inhibition in hepatocytes or HeLa cells).
3. Treat cells for 1–24 hours, depending on assay endpoints (e.g., Western blot for ACC phosphorylation, autophagy markers, or metabolic flux analyses).
4. Include vehicle controls (DMSO only) and, when possible, positive controls (e.g., AICAR for AMPK activation) for comparative analysis.

2. BMP4-Induced SMAD Phosphorylation Inhibition

1. Pre-treat target cells (e.g., neural progenitors, embryonic stem cells) with Dorsomorphin at 0.5–5 μM for 30–60 minutes.
2. Stimulate with BMP4 and monitor SMAD 1/5/8 phosphorylation via Western blot or immunocytochemistry after 30–90 minutes.
3. Quantify effects on downstream gene expression (e.g., hepcidin, neural differentiation markers) using qPCR or immunostaining.

3. Animal Studies: Iron Metabolism and Inflammation Models

1. Prepare Dorsomorphin solution in DMSO or compatible vehicle for intraperitoneal administration (10 mg/kg body weight).
2. Inject animals (e.g., mice) according to experimental design—single or repeated dosing as required.
3. Monitor endpoints such as hepatic hepcidin mRNA (via qPCR), serum iron levels, and histological markers of inflammation or ossification.

For detailed, scenario-driven guidance on protocol design, see the complementary resource, "Dorsomorphin (Compound C): Reliable AMPK & BMP Inhibition in Cell-Based Assays", which addresses common laboratory challenges and protocol optimization strategies.

Advanced Applications and Comparative Advantages

Modulating Autophagy and Cellular Metabolism

Dorsomorphin’s robust inhibition of AMPK and suppression of downstream ACC phosphorylation provide a direct tool to investigate autophagy regulation and metabolic reprogramming. This is particularly relevant for studies of muscle atrophy, metabolic syndrome, and cancer metabolism. Quantitative studies show up to 80% inhibition of ACC phosphorylation in responsive cell types, with downstream effects on fatty acid synthesis and mitochondrial function ("Decoding AMPK and BMP Pathways").

Neural Stem Cell Differentiation and Regenerative Medicine

By targeting the BMP/Smad pathway, Dorsomorphin promotes the self-renewal and neural induction of human embryonic stem cells. This positions it as a powerful tool in neural differentiation protocols, facilitating the development of neural precursors for disease modeling and regenerative research. Its effects complement and extend those described in "Strategic Deployment of Dual-Pathway Inhibitors", which highlights its value in both stem cell engineering and translational neural regeneration.

Iron Metabolism Modulation and Hepcidin Regulation

In vivo studies demonstrate that Dorsomorphin decreases hepatic hepcidin gene transcription and increases serum iron, offering an experimental model for iron homeostasis in health and disease. This capability is particularly relevant for metabolic, inflammatory, and anemic conditions where iron regulation is disrupted.

Cancer Research and Metabolic Disease Models

The ability to inhibit AMPK signaling, modulate autophagy, and interfere with BMP/Smad signaling makes Dorsomorphin a preferred tool in oncology and metabolic disease research, enabling the dissection of cell survival pathways, tumor metabolism, and chemoresistance mechanisms.

Troubleshooting and Optimization Tips

• Solubility Issues: If Dorsomorphin fails to dissolve fully in DMSO, increase the temperature gently (avoid exceeding 37°C) and/or apply ultrasonic treatment. Do not attempt to dissolve in water or ethanol.
• Stock Stability: Prepare fresh DMSO stocks immediately before each experiment. Avoid long-term storage of solutions; aliquot the solid at -20°C for maximum stability.
• Dose Optimization: Empirically determine the optimal concentration for each application. While 10–20 μM is typical for AMPK inhibition in cell lines, some systems (e.g., neural differentiation) may require lower doses (0.5–5 μM) for BMP/Smad pathway modulation.
• Off-Target Effects: Though highly selective, at higher concentrations Dorsomorphin may exhibit off-target kinase inhibition. Include appropriate controls and, where feasible, corroborate findings with genetic or orthogonal pharmacological approaches.
• Assay Timing: The duration of exposure can impact pathway specificity. For acute phosphorylation assays (e.g., SMAD, ACC), shorter incubation (30–60 minutes) is recommended; for autophagy or differentiation endpoints, longer exposures (6–48 hours) may be necessary.
• Interpreting Metabolic Effects: When using Dorsomorphin in metabolic or inflammatory models, carefully monitor cellular ATP/ADP ratios and metabolic flux to distinguish primary from secondary effects.

For troubleshooting guidance on mitochondrial quality control and skeletal muscle metabolism workflows, see "Precision AMPK and BMP Inhibition: Mitochondrial and Muscle Research", which delves into experimental nuances of autophagy regulation.

Future Outlook: Integrating Dorsomorphin into Next-Gen Disease Models

The translational impact of Dorsomorphin (Compound C) is poised to expand as research into metabolic disease, inflammation, and regenerative medicine advances. Recent studies, such as Lei et al. (2025), underscore its value in dissecting the AMPK signaling pathway’s role in immune cell polarization and airway inflammation—a paradigm applicable to obesity, asthma, and chronic inflammatory disease. Its dual function as an AMPK inhibitor and BMP signaling inhibitor uniquely positions it to bridge metabolic, developmental, and disease-focused investigations.

Emerging directions include combinatorial screens with other kinase modulators, single-cell pathway analysis, and the development of lineage-specific stem cell therapies. Dorsomorphin’s precision, coupled with its robust performance in both in vitro and in vivo models, ensures its continued relevance for next-generation biomedical research.

To integrate Dorsomorphin (Compound C) into your workflows, visit the APExBIO product page for detailed specifications, ordering, and technical support.